[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

YU81991A - Sinergističke terapeutske kompozicije i postupci - Google Patents

Sinergističke terapeutske kompozicije i postupci

Info

Publication number
YU81991A
YU81991A YU81991A YU81991A YU81991A YU 81991 A YU81991 A YU 81991A YU 81991 A YU81991 A YU 81991A YU 81991 A YU81991 A YU 81991A YU 81991 A YU81991 A YU 81991A
Authority
YU
Yugoslavia
Prior art keywords
synergistic therapeutic
angiotensin
mammals
blood pressure
methods
Prior art date
Application number
YU81991A
Other languages
English (en)
Serbian (sr)
Other versions
YU49094B (sh
Inventor
Anthony Andrea Fossa
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24080550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU81991(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU81991A publication Critical patent/YU81991A/sh
Publication of YU49094B publication Critical patent/YU49094B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SINERGISTIČKE TERAPEUTSKE KOMPOZICIJE I POSTUPCI, opisane su sinergističke terapeutske kompozicije i postupci pomoću kojih se postiže ostvarenje terapeutskog efekta kao što je snižavanje krvnog pritiska i tretiranje kongestivnog poremećaja rada srca kod sisara, pri čemu sinergističke kompozicije sadrže količine od najmanje dva terapeutska sredstva odabrana iz grupe koju sačinjavaju inhibitor renina, inhibotor enzima koji pretvara angiotenzin I i antagonist angiotenzina II, s time što su inhibitori i antagonisti prisutni u količinama dovoljnim da prouzrokuju sinergističke terapeutske efekte kao što je snižavanje krvnog pritiska i tretiranje kongestivnog poremećaja rada srca kod sisara; zatim postupci za ostvarivanje sinergističkih terapeutskih efekata kao što je snižavanje krvog pritiska i tretiranje kongestivnog poremećaja rada srca, postupci koji obuhvataju davanje pomenutim sisarima, ili sekvencijalno bilo kojim redom ili simultano, količine od najmanje dva terapeutska sredstva odabrana iz grupe koju sačinjavaju inhibitor renina, inhibitor enzima koji pretvara angiotenzin I i antagonist angiotenzina II, u količinama koje su dovoljne da ostvare sinergistički terapeutski efekat.
YU81991A 1990-05-11 1991-05-10 Postupak za dobijanje sinergističke terapeutske kompozicije YU49094B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52236090A 1990-05-11 1990-05-11

Publications (2)

Publication Number Publication Date
YU81991A true YU81991A (sh) 1994-06-24
YU49094B YU49094B (sh) 2003-12-31

Family

ID=24080550

Family Applications (1)

Application Number Title Priority Date Filing Date
YU81991A YU49094B (sh) 1990-05-11 1991-05-10 Postupak za dobijanje sinergističke terapeutske kompozicije

Country Status (34)

Country Link
US (2) US6900234B1 (sh)
EP (1) EP0527879B1 (sh)
JP (2) JPH0729938B2 (sh)
KR (1) KR970005839B1 (sh)
CN (7) CN1065140C (sh)
AP (1) AP240A (sh)
AT (1) ATE148632T1 (sh)
AU (1) AU653724B2 (sh)
BG (1) BG61831B1 (sh)
BR (1) BR9106438A (sh)
CA (1) CA2081564C (sh)
DE (1) DE69124598T2 (sh)
DK (1) DK0527879T3 (sh)
EG (1) EG19648A (sh)
ES (1) ES2097208T3 (sh)
GR (1) GR3022997T3 (sh)
GT (1) GT199100032A (sh)
HK (1) HK1094148A1 (sh)
HU (1) HU227346B1 (sh)
IE (1) IE911592A1 (sh)
IL (1) IL98055A (sh)
IS (1) IS2042B (sh)
MA (1) MA22150A1 (sh)
MY (1) MY114347A (sh)
NO (1) NO924321L (sh)
NZ (1) NZ238118A (sh)
PE (1) PE30891A1 (sh)
PT (1) PT97615B (sh)
RO (1) RO115786B1 (sh)
RU (1) RU2147875C1 (sh)
TW (1) TW203553B (sh)
WO (1) WO1991017771A1 (sh)
YU (1) YU49094B (sh)
ZA (1) ZA913539B (sh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2081564C (en) * 1990-05-11 1998-02-03 Anthony Andrea Fossa Synergistic therapeutic compositions and methods
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
DE4340437C1 (de) * 1993-11-27 1995-05-24 Karla Dr Lehmann Verwendung von Lithiumverbindungen zur Behandlung von Herzinsuffizienz einschließlich ihrer Folgeerkrankungen
WO1996031234A1 (en) * 1995-04-07 1996-10-10 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
CZ297941B6 (cs) 1996-04-05 2007-05-02 Takeda Pharmaceutical Company Limited Farmaceutický prípravek obsahující slouceninu s antagonickým úcinkem k angiotensinu II
WO1997049392A1 (en) * 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
US6248724B1 (en) 1997-09-25 2001-06-19 University Of Florida Antisense oligonucleotide compositions targeted to angiotensin converting enzyme MRNA and methods of use
BR9814422A (pt) * 1997-12-23 2000-10-10 Warner Lambert Co Combinações de inibidor de ace - inibidor de mmp
US6087343A (en) * 1998-09-14 2000-07-11 University Of Florida Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1531879A1 (en) * 2002-06-28 2005-05-25 Novartis AG Use of organic compounds
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
EP2248520A3 (en) * 2004-10-08 2010-11-17 Novartis AG Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN104248763A (zh) * 2005-03-07 2014-12-31 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
PL2139890T3 (pl) 2007-03-29 2014-11-28 Wyeth Llc Antagoniści obwodowych receptorów opioidowych i ich zastosowania
PE20130480A1 (es) 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CN102423483A (zh) * 2011-11-24 2012-04-25 西北农林科技大学 一种复方雷米普利纳米乳抗高血压药物
CN114032273B (zh) * 2021-11-17 2024-02-02 山东省科学院生物研究所 一种多功能西洋参水解肽及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US324377A (en) * 1885-08-18 Roller-skate
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4814342A (en) 1986-10-31 1989-03-21 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
US4895834A (en) * 1986-12-15 1990-01-23 Warner-Lambert Company Renin inhibitors III
US4962105A (en) 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
CA2081564C (en) * 1990-05-11 1998-02-03 Anthony Andrea Fossa Synergistic therapeutic compositions and methods

Also Published As

Publication number Publication date
MY114347A (en) 2002-10-31
CN1056426A (zh) 1991-11-27
JP2635291B2 (ja) 1997-07-30
CA2081564C (en) 1998-02-03
CN1824315A (zh) 2006-08-30
IE911592A1 (en) 1991-11-20
EG19648A (en) 1995-09-30
JPH0729938B2 (ja) 1995-04-05
EP0527879A1 (en) 1993-02-24
IS2042B (is) 2005-09-15
BR9106438A (pt) 1993-05-18
TW203553B (sh) 1993-04-11
AU653724B2 (en) 1994-10-13
PE30891A1 (es) 1991-11-27
JPH0748280A (ja) 1995-02-21
CN1879884A (zh) 2006-12-20
IS3703A7 (is) 1991-11-12
CN101156949A (zh) 2008-04-09
AP9100258A0 (en) 1991-07-31
HU9203522D0 (en) 1993-01-28
US6900234B1 (en) 2005-05-31
NZ238118A (en) 1997-06-24
KR970005839B1 (ko) 1997-04-21
AU7859191A (en) 1991-12-10
CN1065140C (zh) 2001-05-02
BG61831B1 (bg) 1998-07-31
PT97615A (pt) 1992-03-31
ZA913539B (en) 1992-12-30
YU49094B (sh) 2003-12-31
IL98055A0 (en) 1992-06-21
DK0527879T3 (da) 1997-07-14
MA22150A1 (fr) 1991-12-31
US6716875B1 (en) 2004-04-06
JPH05505618A (ja) 1993-08-19
NO924321D0 (no) 1992-11-10
CN1824315B (zh) 2011-01-12
HU227346B1 (en) 2011-04-28
CN1502370A (zh) 2004-06-09
WO1991017771A1 (en) 1991-11-28
EP0527879B1 (en) 1997-02-05
ATE148632T1 (de) 1997-02-15
CN1915428A (zh) 2007-02-21
ES2097208T3 (es) 1997-04-01
NO924321L (no) 1993-01-08
RU2147875C1 (ru) 2000-04-27
RO115786B1 (ro) 2000-06-30
PT97615B (pt) 1998-08-31
DE69124598T2 (de) 1997-05-28
IL98055A (en) 1996-10-31
CN100358578C (zh) 2008-01-02
AP240A (en) 1993-02-18
DE69124598D1 (de) 1997-03-20
CA2081564A1 (en) 1991-11-12
GT199100032A (es) 1992-10-31
HUT62804A (en) 1993-06-28
GR3022997T3 (en) 1997-07-30
BG97068A (bg) 1993-12-24
CN1307901A (zh) 2001-08-15
HK1094148A1 (en) 2007-03-23

Similar Documents

Publication Publication Date Title
YU81991A (sh) Sinergističke terapeutske kompozicije i postupci
RU92016534A (ru) Синергетические терапевтические композиции и способы достижения синергетического терапевтического эффекта
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
CY1110282T1 (el) Ενωσεις για την αγωγη της απωλειας βαρους
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
DOP2004001052A (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
PL402389A1 (pl) Sposób hamowania aktywnosci kinazy Raf u ludzi lub zwierzat
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
ES2108120T3 (es) Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
BR9608041B8 (pt) Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório.
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
CO4410317A1 (es) Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos.
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
PT1185649E (pt) Promotor do gene da miostatina e inibicao da sua activacao
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
BR9809848A (pt) Composição
CL2022002699A1 (es) Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
EE9800315A (et) Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
YU6396A (sh) Kombinacija inhibitora hiv proteaze sa drugim jedinjenjima za terapiju hiv infekcija
ES2171449T3 (es) Reduccion del olor a verraco en la carne.
NO329889B1 (no) Anvendelse av et imidazolderivat til fremstilling av et legemiddel til a forhindre eller behandle hypotensjon og sjokk som skyldes lav perifer motstand, eller kardiopulmonaer gjenopplivning